KSM-66 is a branded, root-only extract of ashwagandha, standardised so that withanolides meet a stated minimum. That gives you a more identifiable ingredient than a label that says only “ashwagandha powder”. It does not mean KSM-66 is guaranteed to reduce stress, improve sleep or suit everyone.
To understand what KSM-66 ashwagandha is, separate four label facts: plant part, extract weight, withanolide percentage and daily serving. Then look at the exact research and current safety questions. Standardisation improves consistency; it is not a clinical verdict.
Root, leaf and the whole plant are not interchangeable
Ashwagandha is Withania somnifera. Supplements can use root powder, leaf, mixtures of root and leaf, or concentrated extracts. Traditional-use narratives often focus on the root, while modern products vary. If one trial used a root-only extract, it does not validate a leaf-heavy product simply because the species name matches.
KSM-66 is positioned as root-only. That is a useful identity marker for comparing a study with a label. Another branded extract may use a different process, plant-part ratio or standardisation. “Ashwagandha 600mg” is not enough detail for a research match.
What withanolides tell you
Withanolides are a family of naturally occurring compounds used as standardisation markers. A minimum 5% means at least 5g of measured withanolides per 100g of extract. In a 500mg extract, 5% corresponds to at least 25mg by simple arithmetic.
This calculation tells you about composition. It does not mean 25mg is an established effective or safe dose. Assay methods and the profile of individual withanolides can differ, so a percentage is more informative when linked to a named material and quality specification.
How to match a trial properly
Use PubMed's KSM-66 search and write down six features: exact branded extract, participant group, daily dose, duration, primary outcome and funding. Stress scores in adults reporting stress are not the same as treatment of an anxiety disorder. A short sleep questionnaire is not proof of curing insomnia.
Small trials can produce interesting signals while still being vulnerable to selective outcomes, short follow-up and sponsorship bias. Look for replication by independent groups and clinically meaningful differences, not only a low P value.
The safety context is still developing
The UK Committee on Toxicity's July 2026 paper on herb-induced liver injury says its ashwagandha review is ongoing. The UK's Committee on Toxicity is still reviewing the safety of ashwagandha in food supplements. That unresolved assessment is part of a responsible buying decision.
Australia's Therapeutic Goods Administration has also warned about gastrointestinal reactions and a very rare risk of liver injury. Stop and seek medical advice if symptoms such as yellow skin or eyes, dark urine, unusual tiredness, severe nausea, vomiting or abdominal pain occur.
Pregnancy, breastfeeding, liver disease, thyroid conditions, diabetes, autoimmune conditions, planned surgery and medicine use all justify individual advice. Ashwagandha should not be stacked casually with sedatives, thyroid medicine or other products chosen for sleep and stress.
Apply the comparison to Root & Pulse
Root & Pulse Ashwagandha KSM-66 provides 500mg KSM-66 ashwagandha root extract per capsule. It is standardised to minimum 5% withanolides, has 90 capsules per pack and is suitable for vegans. The adult direction is one or two capsules daily with food and water, giving a 45 to 90 day supply.
A standardised extract makes composition more consistent but does not guarantee a personal benefit. The serving range also means 500mg or 1000mg extract per day. Choose a serving only within the product directions and with the relevant professional advice. Do not treat two capsules as automatically more effective than one.
The KSM-66 label scorecard
| Question | Why it matters |
|---|---|
| Is KSM-66 named? | Lets you look for research on the same branded material |
| Root only? | Prevents root research being attached to a different plant-part mix |
| Withanolide minimum? | Shows standardisation, not guaranteed effect |
| Amount per capsule and day? | Serving ranges can double daily exposure |
| Safety and medicines checked? | Botanical does not mean interaction-free |
| Outcome precisely described? | Stress, anxiety disorder and sleep are different claims |
When not buying is the better decision
If you want a treatment for persistent anxiety or insomnia, if you take interacting medicines, or if the safety uncertainties make you uncomfortable, a supplement purchase is not the right next step. Sleep timing, caffeine, light exposure, movement and appropriate clinical support can be more useful.
Compare other options in the Sleep & Stress collection and read our evening routine guide. A named extract improves transparency. It does not remove the need for judgement.
Compare three imaginary ashwagandha labels
Product A states “ashwagandha 1000mg” but does not say root, leaf, powder or extract. The number looks large, yet identity is weak. Product B provides 300mg of a 10:1 root-and-leaf extract with no marker percentage. Concentration is described, but chemical standardisation is unclear. Product C provides 500mg named root-only extract at minimum 5% withanolides. It is easiest to match with research on that material.
Product C wins on transparency, not automatic effectiveness. If its research is small, short, funded by the ingredient company or focused on a different outcome, the stronger label cannot repair the evidence.
Set a stop rule before starting
Do not make an open-ended botanical experiment. Record the reason, medicines, serving and review date. Stop and seek advice for signs of liver trouble, significant gastrointestinal symptoms, palpitations, unusual agitation or another concerning change. Do not increase the serving to chase an effect.
If the reason is stress, define the practical outcome: fewer evenings lost to rumination, a more regular bedtime or feeling able to complete daily tasks. If distress is persistent or severe, the correct outcome is getting appropriate care, not proving that a capsule works.
Named ingredients still need current oversight
A branded extract can improve batch consistency and research traceability. Safety surveillance continues after products reach the market, which is why current authority reviews matter alongside older trials. Check updates again if you return to this decision in several months. Botanical evidence and regulatory assessment do not stand still.
Research language to keep separate
“Reduced a questionnaire score” is not the same as “treats anxiety”. “Improved a sleep score” is not “cures insomnia”. “Well tolerated in this short trial” is not “safe for long-term use in everyone”. Preserve the original outcome and population whenever you summarise a KSM-66 study.
Also note who was excluded. Short trials often exclude pregnancy, major illness, complex medicines and older adults. A tolerability result in selected participants cannot settle suitability for people the study never enrolled. Read the full study protocol as carefully as the abstract.
Sources
- UK Committee on Toxicity: Ashwagandha and herb-induced liver injury
- Therapeutic Goods Administration: Ashwagandha and very rare liver injury risk
- PubMed search: KSM-66 ashwagandha trials
Common questions
Is KSM-66 the same as ordinary ashwagandha powder?
No. KSM-66 is a branded root extract with a stated standardisation. Ordinary powder and other extracts can differ in concentration and plant parts.
How many withanolides are in 500mg at 5%?
Five per cent of 500mg is 25mg, so a minimum 5% specification corresponds to at least 25mg measured withanolides. That is composition arithmetic, not an established benefit dose.
Is ashwagandha proven safe for everyone?
No. UK authorities are assessing safety evidence, and individual advice is important with pregnancy, liver or thyroid concerns, diabetes, medicine use and other medical contexts.
